论文部分内容阅读
在联合化疗方案基础上加用重组人粒细胞集落刺激因子（G－CSF）和重组白细胞介素－2（IL－2）治疗AML22例，并以单用联合化疗方案的18例为对照组，进行疗效随访观察。结果：治疗组完全缓解率81．8％，对照组72．2％（P＞0．05）。到1996年10月，治疗组缓解或4～48个月，中数缓解期19．6个月，生存期6～51个月，中数生存期23个月；对照组中数缓解期13．5个月（4～32个月），中数生存期14．6个月（5～36个月）。治疗组缓解期和生存期优于对照组（P＜0．05）。
On the basis of combined chemotherapy regimens, 22 patients with AML were treated with recombinant human granulocyte colony-stimulating factor (G-CSF) and recombinant interleukin-2 (IL-2), and 18 patients with a single-use chemotherapy regimen were used as a control group. Follow-up observations were performed. Results: The complete remission rate was 81.8% in the treatment group and 72.2% in the control group (P>0.05). By October 1996, the treatment group was relieved or 4 to 48 months, with a median remission period of 19.6 months, a survival period of 6 to 51 months, and a median survival period of 23 months. The control group had an intermediate remission period of 13.9%. Five months (4 to 32 months), median survival time of 14.6 months (5 to 36 months). The remission and survival of the treatment group were superior to those of the control group (P<0.05).